

Clinical outcome following percutaneous coronary intervention in stable coronary artery disease based on a novel index: computational pressure-flow dynamics derived fractional flow reserve

LY Lam¹, CKL Leung¹, KY Li¹, ASY Yu², MZ Wu², QW Ren², PF Wong², YK Tse¹, SSY Yu¹, HL Li¹, KH Yiu² ¹Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong ²Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong

Introduction

Computational pressure-flow dynamics derived fractional flow reserve (caFFR) is a novel index to assess myocardial ischaemia of coronary artery disease (CAD), without the need of invasive pressure wire and hyperaemic stimulus measured by conventional fractional flow reserve (FFR). Nonetheless, the clinical value of caFFR is uncertain.



This study evaluated the clinical outcomes of patients with and

without percutaneous coronary intervention (PCI) in patients with ischaemia defined by caFFR.

Conventional FFR ^{1,2}

- Pressure-derived physiologic index, defined as the ratio of mean distal coronary pressure to mean aortic pressure
- Standard method to evaluate the functional significance of epicardial coronary artery stenosis as a Class IA recommendation, by incorporating stenosis severity, myocardial territory and viability, and collateral perfusion
- Utilizes a specialized guide wire to measure blood pressure within a coronary artery
- Low adoption rate of FFR guided PCI in real-world practice

Results

The number of obstructive lesions was 2.6 \pm 1.5 in patients with PCI and 2.3 \pm 1.4 in those without PCI (P=0.203) and the severity of CAD assessed by SYNTAX score was similar between the two groups (19.8 \pm 10.6 vs 17.8 \pm 9.5, P=0.072).

The rate of primary end point was significantly lower in those with PCI compared with those without PCI (8.1% vs 18.0%; adjusted hazard ratio [HR]=0.49; 95% confidence interval [CI]=0.28-0.88; P=0.016). Recurrent angina was also significantly less in patients with PCI compared with those without PCI (10.3% vs 20.5%; adjusted HR=0.54; 95% CI=0.32-0.92; P=0.005).

Table 2. Primary and Secondary End Points at 3 Years.

multivariate cox regression models for MACE outcomes in patients with ischemic

	Ischemic, with PCI (n=320)	Ischemic, without PCI (n=122)	P value
Composite of death, MI, and any repeat revascularization - no. (%)	26 (8.1)	22 (18.0)	0.003
Recurrent Angina	33 (10.3)	25 (20.5)	0.005

caFFR


- Angiography-based FFR generated by FLASH software using computational pressure-fluid dynamics
- Computational time < 1 minute, total operation time < 5 minutes
- Previously reported accuracy validation³

Methods


A total of 442 patients (mean age: 66.0 ± 10.7 ; 73.1% male) with stable CAD and functional ischaemia defined as caFFR ≤ 0.80 were identified. Patients were subsequently stratified into those with PCI (n=320) and without PCI (n=122).

The primary end point was defined as a composite of all-cause mortality, myocardial infarction or any repeat revascularization at 3 years.

Table 1.	Baseline	Characteristics	of the	Patients



Univariate analysis			Mult	tivariate analysis		
	Hazard Ratio	95% Confidence Interval	P value	Hazard Ratio	95% Confidence Interval	P value
PCI	0.432	0.245-0.761	0.004	0.449	0.247-0.816	0.009
Age	0.999	0.973-1.026	0.937			
Sex	1.654	0.801-3.415	0.173			
History of MI	2.291	1.028-5.106	0.043	2.158	0.898-5.188	0.08
History of PCI	1.324	0.701-2.503	0.387			
Peripheral Vascular	2.700	0.655-11.125	0.169			
Disease						
Cerebrovascular disease	1.162	0.417-3.223	0.774			
Diabetes Mellitus	2.041	1.154-3.611	0.014	1.480	0.773-2.834	0.23
Hypertension	1.419	0.762-2.645	0.270			
Smoker	0.847	0.441-1.628	0.619			
Hyperlipidaemia	1.327	0.752-2.342	0.328			
Family history of CAD	0.830	0.115-6.019	0.854			
Renal disease	6.665	3.315-13.400	0.000	3.852	1.679-8.839	0.00
Beta blocker	0.903	0.513-1.592	0.725			
Calcium antagonist	0.760	0.413-1.400	0.379			
ACEI	1.342	0.756-2.381	0.316			
ARB	1.605	0.778-3.314	0.201			
Diuretics	1.220	0.548-2.720	0.626			
Digoxin	2.372	0.327-17.195	0.393			
Nitrate	0.531	0.281-1.003	0.051	0.537	0.263-1.096	0.08
Statin	0.436	0.243-0.783	0.005	0.354	0.171-0.734	0.00
Insulin injection	2.878	1.434-5.778	0.003	1.558	0.674-3.598	0.30
Anti-DM drugs	0.760	0.395-1.461	0.410			
Aspirin	0.549	0.306-0.984	0.044	1.058	0.522-2.144	0.87
Anti-ADP	1.111	0.578-2.135	0.752			
Anticoagulant	1.142	0.277-4.706	0.854			



Oral Anticoagulant - No. (%)	10 (3.1)	6 (4.9)	0.396
Angiographic Findings Obstructive lesions per patient – no. SYNTAX Score	2.6 ± 1.5 19.8 ± 10.6	2.3 ± 1.4 17.8 ± 9.5	0.203 0.072

0.298

0.605

0.003

0.037

0.225

0.945

0.239

0.590

0.287

0.264

1.000

0.016

0.002 0.297

0.002

0.300

0.028

0.066

0.127

0.107

0.037

0.765

0.640

0.037

¹ Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Jr., Smith SC, Jr., Spertus JA, Williams SV. 2012 accf/aha/acp/aats/pcna/scai/sts guideline for the diagnosis and management of patients with stable ischemic heart disease: Executive summary: A report of the american college of cardiology foundation/american heart association task force on practice guidelines, and the american college of physicians, american association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Journal of the American College of Cardiology. 2012;60:2564-2603

² Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 esc/eacts guidelines on myocardial revascularization: The task force on myocardial revascularization of the european society of cardiology (esc) and the european association for cardio-thoracic surgery (eacts)developed with the special contribution of the european association of percutaneous cardiovascular interventions (eapci). European heart journal. 2014;35:2541-2619

³ Li JP, Gong YJ, Wang WM, Yang Q, Liu B, Lu Y, Xu YW, Huo YL, Yi TC, Liu J, Li Y, Xu SP, Zhao L, Ali ZA, Huo Y. Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR. Cardiovascular Research. 2020; 116(7):1349-1356

Conclusion

In stable CAD patients with myocardial ischaemia defined by caFFR

≤ 0.80, PCI significantly reduces the rate of the composite end point

and recurrent episode of angina compared with those without PCI.

<u>Contact Details</u> Lam Lok Yee Jane (MBBS Year III Student) Email: jane1230@hku.hk Phone: 67120389